Provided by Tiger Fintech (Singapore) Pte. Ltd.

Moderna, Inc.

31.26
-0.9400-2.92%
Post-market: 31.25-0.0100-0.03%19:59 EDT
Volume:7.82M
Turnover:246.38M
Market Cap:12.09B
PE:-3.58
High:32.58
Open:32.45
Low:30.97
Close:32.20
Loading ...

Cautious Hold Rating on Moderna Amid Promising mRNA-1010 Vaccine Results and Methodology Concerns

TIPRANKS
·
30 Jun

Moderna Shares up 5.2% After Co's Experimental Flu Vaccine More Effective Than Approved Shot in Late-Stage Study

THOMSON REUTERS
·
30 Jun

BUZZ-U.S. STOCKS ON THE MOVE-Tech stocks, US big banks, Chime

Reuters
·
30 Jun

Exchange-Traded Funds, Equity Futures Edge Higher Pre-Bell Monday Amid Hopes of Smoother Canada Relations

MT Newswires Live
·
30 Jun

Moderna Stock Jumps 5% Premarket as It Sees Positive Phase 3 Results for Seasonal Flu Vaccine

Dow Jones
·
30 Jun

Stock Track | Moderna Soars 5.15% Pre-market on Positive Phase 3 Results for Influenza Vaccine

Stock Track
·
30 Jun

Moderna's influenza vaccine superior to licensed shot in study

Reuters
·
30 Jun

Moderna Shares up 3.6% Premarket After Co Reports Late-Stage Data for Seasonal Flu Vaccine

THOMSON REUTERS
·
30 Jun

Moderna - Announces Positive Phase 3 Results for Seasonal Influenza Vaccine

THOMSON REUTERS
·
30 Jun

Moderna - in Participants Aged 65 Years and Older, Mrna-1010 Demonstrated an Rve of 27.4%

THOMSON REUTERS
·
30 Jun

Moderna - Mrna-1010 Achieved Stringent Superiority Criterion Prespecified in the Protocol, With an Rve of 26.6% in Overall Study Population

THOMSON REUTERS
·
30 Jun

Moderna - Safety and Tolerability of Mrna-1010 Were Consistent With Reported Results From a Previous Phase 3 Study.

THOMSON REUTERS
·
30 Jun

Moderna - Strong Rve Was Observed for Each Influenza Strain Contained in the Vaccine During Study

THOMSON REUTERS
·
30 Jun

Moderna Inc. Announces Positive Phase 3 Results for mRNA-1010, Demonstrating Superior Efficacy in Seasonal Influenza Vaccine for Older Adults

Reuters
·
30 Jun

Moderately bullish activity in Moderna with shares up 2.64%

TIPRANKS
·
27 Jun

The Anti-Vax Movement Solidifies Control of the CDC's Vaccine Committee -- Barrons.com

Dow Jones
·
27 Jun

US CDC panel broadly recommends flu shots free from thimerosal

Reuters
·
27 Jun

US CDC panel votes in favor of Merck's RSV antibody drug

Reuters
·
26 Jun

US Cdc Vaccine Advisory Panel Meeting Begins

THOMSON REUTERS
·
25 Jun

FACTBOX-Vaccines and antibodies up for debate at CDC advisory panel meeting

Reuters
·
25 Jun